EyePoint Pharmaceuticals, Inc. — Director's Dealing 2020

Mar 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2020-02-28

Reporting Person: Peterson Kristine (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-28	Restricted Stock Units	$0.00	A	19000.00	Acquired		Common Stock (19000.00)	Direct
2020-02-28	Stock Option (Right to Buy)	$1.29	A	33500.00	Acquired	2030-02-28	Common Stock (33500.00)	Direct

Footnotes

F1: Will fully vest on the one-year anniversary of the grant date.